Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Anti-microbial/Anti-fungal Tests Market Outlook (2022 to 2032)

[268 Pages Report] The global anti-microbial/anti-fungal tests market is expected to reach US$ 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~US$ 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.

Attributes Key Insights
Anti-microbial/Anti-fungal Tests Market Value 2021 US$ 2.4 Billion
Estimated Market Size 2022 US$ 2.5 Billion
Projected Market Value 2032 US$ 4.5 Billion
CAGR 2022 to 2032 5.7%
Market Share of Top 5 Countries 55.0%

Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.

Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Anti-microbial/Anti-fungal Tests Market from 2012 to 2021 Vs Demand Outlook for 2022 to 2032

As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~US$ 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.

Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.

As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.

The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.

Anti-microbial/Anti-fungal Tests Market

What are the Key Opportunities in the Anti-microbial/Anti-fungal Tests Kit Market?

  • Favorable Government Initiatives and Awareness Programs to Fuel the Growth

Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.

Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining Demand for Anti-microbial/Anti-fungal Tests?

The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.

Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.

Country-wise Insights

How will the Sales in the USA Anti-microbial/Anti-fungal Tests Market Increase?

Growing Preference for Diagnostic Tests to Boost the Sales

The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.

Will China Retain its Dominance in Anti-microbial/Anti-fungal Tests Market?

Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China

China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.

Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.

It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.

How Big is the Opportunity in Germany's Anti-microbial/Anti-fungal Tests Market?

Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection

Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.

This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Anti-microbial/Anti-fungal Tests Type is Driving the Growth?

Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond

Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.

Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.

Which is the Leading End User in Anti-microbial/Anti-fungal Tests Market?

Nearly 2 out of 5 Sales are Contributed by Hospitals

As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.

Competitive Landscape

With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.

  • In July 2022, Roche announced that Elecsys HCV Duo immunoassay is now available in countries that accept the CE Mark. Elecsys HCV Duo is the only immunoassay on the market that can determine hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
  • In June 2022, Meridian Bioscience, Inc., a global leader in diagnostic testing solutions and life science raw materials, introduced two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These novel master mixes increase the molecular detection of DNA and RNA from crude faecal materials while allowing diagnostic procedures to be room temperature stabilised.

Report Scope as per Anti-microbial/Anti-fungal Tests Industry Analysis

Attribute Details
Estimated Market Size 2022 US$ 2.5 Billion
Projected Market Value 2032 US$ 4.5 Billion
CAGR 2022 to 2032 5.7%
Forecast Period 2012 to 2021
Historical Data Available for 2022 to 2032
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa
Key Market Segments Covered Tests, Infection, End User, and Region
Key Companies Profiled
  • Abbott Laboratories
  • bioMérieux SA
  • Bio-Rad Laboratories Inc
  • Bruker Corporation
  • Danaher Corporation
  • Erba Mannheim
  • F. Hoffmann-La Roche AG
  • Luminex Corporation
  • Meridian Bioscience Inc
  • Norgen Biotek Corp
  • Omega Diagnostics Group Plc
  • Qiagen N.V
  • Quidel Corporation
  • Thermo Fisher Scientific Inc

Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research

By Tests Type:

  • Molecular Based Tests
    • PCR Test
    • DNA Microarray
  • Phenotypic Resistance Tests
  • Complex Test Panels
  • Mass Spectrometry
  • Rapid Diagnostic Tests
    • E-Test Antibiotic/Antifungal Strips
    • Biosensor Platforms

By Infection Type:

  • Antimicrobial Resistance
    • Methicillin-Resistant Staphylococcus Aureus
    • Vancomycin-Resistant Enterococcus
    • Multi-Drug-Resistant Mycobacterium tuberculosis
    • Carbapenem-Resistant Enterobacteriaceae gut bacteria
  • Microbial Infection
  • Antifungal Resistance
    • Candida infections
    • Aspergillus infection
    • Fusariosis
    • Others
  • Fungal Infection

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Community Health Centers
  • Reference Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How much was the anti-microbial/anti-fungal tests market worth in 2021?

The global anti-microbial/anti-fungal tests market is worth US$ 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.

What is the sales forecast for the anti-microbial/anti-fungal tests market through 2032?

The anti-microbial/anti-fungal tests market is expected to reach US$ 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.

What are the key trends shaping the anti-microbial/anti-fungal tests market?

The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.

Which are the top five countries driving demand for anti-microbial/anti-fungal tests?

USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.

What is the North American market outlook for anti-microbial/anti-fungal tests?

North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in Europe?

Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.

At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in MEA?

Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.

Which countries are the key producers of anti-microbial/anti-fungal tests?

China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.

Who are the key players in the anti-microbial/anti-fungal tests market sphere?

Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.

Table of Content

1. Executive Summary | Anti-microbial/Anti-fungal Tests Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Epidemiology of Key Indication, By Region

    4.2. Key Promotional Strategies

    4.3. Patient Journey

    4.4. Regulatory Scenario

    4.5. Reimbursement Landscape

    4.6. PESTEL analysis

    4.7. Porter’s analysis

    4.8. Value Chain

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare GDP Growth Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rising Prevalence of infectious diseases.

        5.2.2. Increasing Awareness and Adoption.

        5.2.3. Increase in rapid diagnostics tests.

        5.2.4. Increasing prevalence of antimicrobial resistance patients.

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

    5.4. Global Supply Demand Analysis

6. COVID-19 Crisis - Crisis Analysis

    6.1. COVID-19 and Impact Analysis

    6.2. 2021 Market Scenario

        6.2.1. By Tests Type

        6.2.2. By Infection Type

        6.2.3. By End User

        6.2.4. By Region

7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032

    7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021

    7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Tests Type, 2012 to 2021

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests Type, 2022 to 2032

        8.3.1. Molecular-Based Tests

            8.3.1.1. PCR Test

            8.3.1.2. DNA Microarray

        8.3.2. Phenotypic Resistance Tests

        8.3.3. Complex Test Panels

        8.3.4. Mass Spectrometry

        8.3.5. Rapid Diagnostic Tests

            8.3.5.1. E-Test Antibiotic/Antifungal Strips

            8.3.5.2. Biosensor Platforms

    8.4. Market Attractiveness Analysis By Tests Type

9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis, By Infection Type, 2012 to 2021

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Infection Type, 2022 to 2032

        9.3.1. Antimicrobial Resistance

            9.3.1.1. Methicillin-Resistant Staphylococcus Aureus

            9.3.1.2. Vancomycin-Resistant Enterococcus

            9.3.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis

            9.3.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria

        9.3.2. Microbial Infection

        9.3.3. Antifungal Resistance

            9.3.3.1. Candida infections

            9.3.3.2. Aspergillus infection

            9.3.3.3. Fusariosis

            9.3.3.4. Others

        9.3.4. Fungal Infection

    9.4. Market Attractiveness Analysis By Infection Type

10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021

    10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032

        10.3.1. Hospitals

        10.3.2. Ambulatory Surgical Centers

        10.3.3. Clinics

        10.3.4. Community Health Centers

        10.3.5. Reference Laboratories

    10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        12.3.1. By Country

            12.3.1.1. United States of America

            12.3.1.2. Canada

        12.3.2. By Tests Type

        12.3.3. By Infection Type

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Tests Type

        12.4.3. By Infection Type

        12.4.4. By End User

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country-Level Analysis & Forecast

        12.8.1. USA Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Tests Type

                12.8.1.2.2. By Infection Type

                12.8.1.2.3. By End User

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Tests Type

                12.8.2.2.2. By Infection Type

                12.8.2.2.3. By End User

13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        13.3.1. By Country

            13.3.1.1. Mexico

            13.3.1.2. Brazil

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Tests Type

        13.3.3. By Infection Type

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Tests Type

        13.4.3. By Infection Type

        13.4.4. By End User

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country-Level Analysis & Forecast

        13.8.1. Mexico Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Tests Type

                13.8.1.2.2. By Infection Type

                13.8.1.2.3. By End User

        13.8.2. Brazil Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Tests Type

                13.8.2.2.2. By Infection Type

                13.8.2.2.3. By End User

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Tests Type

                13.8.3.2.2. By Infection Type

                13.8.3.2.3. By End User

14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. United Kingdom

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Tests Type

        14.3.3. By Infection Type

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Tests Type

        14.4.3. By Infection Type

        14.4.4. By End User

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country-Level Analysis & Forecast

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Tests Type

                14.8.1.2.2. By Infection Type

                14.8.1.2.3. By End User

        14.8.2. Italy Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Tests Type

                14.8.2.2.2. By Infection Type

                14.8.2.2.3. By End User

        14.8.3. France Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Tests Type

                14.8.3.2.2. By Infection Type

                14.8.3.2.3. By End User

        14.8.4. UK Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Tests Type

                14.8.4.2.2. By Infection Type

                14.8.4.2.3. By End User

        14.8.5. Spain Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Tests Type

                14.8.5.2.2. By Infection Type

                14.8.5.2.3. By End User

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Tests Type

                14.8.6.2.2. By Infection Type

                14.8.6.2.3. By End User

        14.8.7. Russia Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Tests Type

                14.8.7.2.2. By Infection Type

                14.8.7.2.3. By End User

15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    15.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Malaysia

            15.3.1.4. Thailand

            15.3.1.5. Rest of South Asia

        15.3.2. By Tests Type

        15.3.3. By Infection Type

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Tests Type

        15.4.3. By Infection Type

        15.4.4. By End User

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country-Level Analysis & Forecast

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Tests Type

                15.8.1.2.2. By Infection Type

                15.8.1.2.3. By End User

        15.8.2. Indonesia Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Tests Type

                15.8.2.2.2. By Infection Type

                15.8.2.2.3. By End User

        15.8.3. Malaysia Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Tests Type

                15.8.3.2.2. By Infection Type

                15.8.3.2.3. By End User

        15.8.4. Thailand Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Tests Type

                15.8.4.2.2. By Infection Type

                15.8.4.2.3. By End User

16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Tests Type

        16.3.3. By Infection Type

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Tests Type

        16.4.3. By Infection Type

        16.4.4. By End User

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country-Level Analysis & Forecast

        16.8.1. China Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Tests Type

                16.8.1.2.2. By Infection Type

                16.8.1.2.3. By End User

        16.8.2. Japan Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Tests Type

                16.8.2.2.2. By Infection Type

                16.8.2.2.3. By End User

        16.8.3. South Korea Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Tests Type

                16.8.3.2.2. By Infection Type

            16.8.3.3. By End User

17. Oceania Market 2017 to 2021 and Forecast 2022 to 2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Tests Type

        17.3.3. By Infection Type

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Tests Type

        17.4.3. By Infection Type

        17.4.4. By End User

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country-Level Analysis & Forecast

        17.8.1. Australia Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Tests Type

                17.8.1.2.2. By Infection Type

                17.8.1.2.3. By End User

        17.8.2. New Zealand Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Tests Type

                17.8.2.2.2. By Infection Type

                17.8.2.2.3. By End User

18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021

    18.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Turkey

            18.3.1.3. South Africa

            18.3.1.4. North Africa

        18.3.2. By Tests Type

        18.3.3. By Infection Type

        18.3.4. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Tests Type

        18.4.3. By Infection Type

        18.4.4. By End User

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country-Level Analysis & Forecast

        18.8.1. GCC Countries Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Tests Type

                18.8.1.2.2. By Infection Type

                18.8.1.2.3. By End User

        18.8.2. Turkey Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Tests Type

                18.8.2.2.2. By Infection Type

                18.8.2.2.3. By End User

        18.8.3. South Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Tests Type

                18.8.3.2.2. By Infection Type

                18.8.3.2.3. By End User

        18.8.4. North Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Tests Type

                18.8.4.2.2. By Infection Type

                18.8.4.2.3. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

    19.3. Market Presence Analysis

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive

        20.3.1. Abbott Laboratories

            20.3.1.1. Overview

            20.3.1.2. Product Portfolio

            20.3.1.3. Fey Financials

            20.3.1.4. Sales Footprint

            20.3.1.5. Strategy Overview

        20.3.2. bioMérieux SA,

            20.3.2.1. Overview

            20.3.2.2. Product Portfolio

            20.3.2.3. Fey Financials

            20.3.2.4. Sales Footprint

            20.3.2.5. Strategy Overview

        20.3.3. Bio-Rad Laboratories Inc.,

            20.3.3.1. Overview

            20.3.3.2. Product Portfolio

            20.3.3.3. Fey Financials

            20.3.3.4. Sales Footprint

            20.3.3.5. Strategy Overview

        20.3.4. Bruker Corporation,

            20.3.4.1. Overview

            20.3.4.2. Product Portfolio

            20.3.4.3. Fey Financials

            20.3.4.4. Sales Footprint

            20.3.4.5. Strategy Overview

        20.3.5. Danaher Corporation,

            20.3.5.1. Overview

            20.3.5.2. Product Portfolio

            20.3.5.3. Fey Financials

            20.3.5.4. Sales Footprint

            20.3.5.5. Strategy Overview

        20.3.6. Erba Mannheim,

            20.3.6.1. Overview

            20.3.6.2. Product Portfolio

            20.3.6.3. Fey Financials

            20.3.6.4. Sales Footprint

            20.3.6.5. Strategy Overview

        20.3.7. F. Hoffmann-La Roche AG,

            20.3.7.1. Overview

            20.3.7.2. Product Portfolio

            20.3.7.3. Fey Financials

            20.3.7.4. Sales Footprint

            20.3.7.5. Strategy Overview

        20.3.8. Luminex Corporation,

            20.3.8.1. Overview

            20.3.8.2. Product Portfolio

            20.3.8.3. Fey Financials

            20.3.8.4. Sales Footprint

            20.3.8.5. Strategy Overview

        20.3.9. Meridian Bioscience Inc.,

            20.3.9.1. Overview

            20.3.9.2. Product Portfolio

            20.3.9.3. Fey Financials

            20.3.9.4. Sales Footprint

            20.3.9.5. Strategy Overview

        20.3.10. Norgen Biotek Corp.,

            20.3.10.1. Overview

            20.3.10.2. Product Portfolio

            20.3.10.3. Fey Financials

            20.3.10.4. Sales Footprint

            20.3.10.5. Strategy Overview

        20.3.11. Omega Diagnostics Group Plc.,

            20.3.11.1. Overview

            20.3.11.2. Product Portfolio

            20.3.11.3. Fey Financials

            20.3.11.4. Sales Footprint

            20.3.11.5. Strategy Overview

        20.3.12. Qiagen N.V.,

            20.3.12.1. Overview

            20.3.12.2. Product Portfolio

            20.3.12.3. Fey Financials

            20.3.12.4. Sales Footprint

            20.3.12.5. Strategy Overview

        20.3.13. Quidel Corporation,

            20.3.13.1. Overview

            20.3.13.2. Product Portfolio

            20.3.13.3. Fey Financials

            20.3.13.4. Sales Footprint

            20.3.13.5. Strategy Overview

        20.3.14. Thermo Fisher Scientific Inc.

            20.3.14.1. Overview

            20.3.14.2. Product Portfolio

            20.3.14.3. Fey Financials

            20.3.14.4. Sales Footprint

            20.3.14.5. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Fertility and Pregnancy Rapid Test Kit Market

Published : October 2023

Healthcare

Fungal Keratitis Treatment Market

Published : August 2023

Healthcare

Fungal Testing Kits Market

Published : March 2023

Healthcare

At-Home Vaginal pH Test Kit Market

Published : June 2022

Explore Healthcare Insights

View Reports

Anti-microbial/Anti-fungal Tests Market